公开(公告)号：US12130293B2

公开(公告)日：2024-10-29

申请号：US17746341

申请日：2022-05-17

Applicant: ShOx Science Limited

Inventor： Bevin Gangadharan ,  Abhinav Kumar ,  Raymond A. Dwek ,  Nicole Zitzmann ,  Mark Thursz ,  Jeremy Francis Lars Cobbold

IPC: G01N33/68

CPC classification number: G01N33/6893 ,  G01N2333/775 ,  G01N2333/811 ,  G01N2800/085 ,  G01N2800/56

Abstract: The invention relates to methods of diagnosing, prognosing, or monitoring or staging the progression of non-alcoholic fatty liver disease (NAFLD) using biomarkers. The invention also relates to a method of scoring to determine the severity of NAFLD, and a method of treating NAFLD.

公开(公告)号：US20240329053A1

公开(公告)日：2024-10-03

申请号：US18293087

申请日：2022-08-02

Applicant: TZARTOS NEURODIAGNOSTICS

Inventor： John TZARTOS ,  Socrates TZARTOS

IPC: G01N33/68 ,  G01N1/30

CPC classification number: G01N33/6854 ,  G01N1/30 ,  G01N33/6893 ,  G01N2001/305

Abstract: Cell-based method for detecting antibodies against subunits of the neuronal nicotinic acetylcholine receptors in a subject is disclosed. The method comprises steps of



engineering cells to express at least one protein;
optionally, culturing said cells with at least one substance;
exposing said cells to body fluid or tissue from subject; and
detecting a reaction between at least one protein and antibodies found in body fluid or tissue,
obtaining a diagnosis for the patient.




A kit is also disclosed for detecting antibodies against subunits of the nicotinic acetylcholine receptors in a subject. The kit comprises cells expressing at least one protein; at least one medium for cell culture, at least one buffer for cell culture; and optionally, at least one substance.

公开(公告)号：US12105099B2

公开(公告)日：2024-10-01

申请号：US17715294

申请日：2022-04-07

Applicant: Richard Eng ,  Cassandra Parent ,  Amal Hayat ,  Amanda Ruci ,  Anvith Krishnan ,  Feiyang Huang ,  Eric Simon ,  Ellie Zhang

Inventor： Richard Eng ,  Cassandra Parent ,  Amal Hayat ,  Amanda Ruci ,  Anvith Krishnan ,  Feiyang Huang ,  Eric Simon ,  Ellie Zhang

IPC: G01N33/53 ,  G01N33/543 ,  G01N33/553 ,  G01N33/68 ,  B82Y5/00 ,  B82Y40/00

CPC classification number: G01N33/6893 ,  G01N33/54346 ,  G01N33/54388 ,  G01N33/553 ,  B82Y5/00 ,  B82Y40/00

Abstract: This disclosure provides methods and devices for determining a quantitative estimate of syndecan-1 levels in a mammalian subject suspected of internal hemorrhaging. The method includes applying a blood sample from the subject to a hand-held assay device capable of providing optical quantitation of the amount of syndecan-1 in the sample, measuring, by means of said assay device, an analyte signal value correlated to a concentration of the syndecan-1 in the blood sample and comparing the analyte signal value to a minimum threshold, wherein an analyte signal value less than the minimum threshold indicates that the subject is not internally hemorrhaging, and an analyte signal value above the minimum threshold indicates the subject is internally hemorrhaging. The methods and devices are adapted to rapidly assess internal hemorrhaging and hemorrhagic shock in a patient outside of hospital settings.

公开(公告)号：US12099068B2

公开(公告)日：2024-09-24

申请号：US17749376

申请日：2022-05-20

Applicant: Incyte Corporation

Inventor： Michael D. Howell ,  Hao Liu ,  Michael A. Pratta

IPC: G01N33/68 ,  A61K31/519 ,  A61K31/573 ,  A61K45/06 ,  A61P37/06

CPC classification number: G01N33/6893 ,  A61K31/519 ,  A61K31/573 ,  A61K45/06 ,  A61P37/06 ,  G01N2800/245 ,  G01N2800/52 ,  G01N2800/60

Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing Graft-Versus-Host Disease.

公开(公告)号：US20240310385A1

公开(公告)日：2024-09-19

申请号：US18277838

申请日：2022-02-16

Applicant: Nightingale Health Oyj

Inventor： Heli Julkunen ,  Peter Würtz

IPC: G01N33/68 ,  G01N24/08 ,  G01N33/92

CPC classification number: G01N33/6893 ,  G01N24/08 ,  G01N33/92 ,  G01N2800/50

Abstract: A method for determining whether a subject is at risk of developing certain circulatory diseases is disclosed.

公开(公告)号：US20240310377A1

公开(公告)日：2024-09-19

申请号：US18544966

申请日：2023-12-19

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Kusumam Joseph ,  Allen A. Kaplan

IPC: G01N33/573 ,  C07K14/435 ,  C07K16/38 ,  C07K16/40 ,  C12Q1/37 ,  G01N33/68

CPC classification number: G01N33/573 ,  C07K14/435 ,  C07K16/38 ,  C07K16/40 ,  C12Q1/37 ,  G01N33/6893 ,  C07K2317/21 ,  C07K2317/76 ,  G01N2333/4706 ,  G01N2333/8121 ,  G01N2333/96455 ,  G01N2333/96458 ,  G01N2800/32 ,  G01N2800/52 ,  G01N2800/70

Abstract: The invention provides assay methods of detecting plasma protease C1 inhibitor (C1-INH) that binds plasma kallikrein, Factor XII, or both, and uses thereof for identifying subjects at risk for or suffering from a pKal-mediated or bradykinin-mediated disorder. Provided methods permit analysis of patients with plasma kallikrein-mediated angioedema (KMA), or other diseases mediated by pKal useful in the evaluation and treatment.

公开(公告)号：US20240310363A1

公开(公告)日：2024-09-19

申请号：US18625699

申请日：2024-04-03

Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

Inventor： Prashanth Vallabhajosyula

IPC: G01N33/50 ,  C12Q1/6883 ,  G01N33/68

CPC classification number: G01N33/5076 ,  C12Q1/6883 ,  G01N33/6893 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Q2600/178 ,  G01N2800/042 ,  G01N2800/245 ,  G01N2800/50 ,  G01N2800/52

Abstract: This present disclosure relates to the use of one or more biomarkers to monitor the conditional state of an organ or tissue, including transplanted tissue, or disease state, including diabetes, in a biological sample of a subject. Accordingly, this disclosure provides for: methods and kits for determining the presence of one or more biomarkers for organ or tissue rejection/injury or diabetes in a biological sample of a subject; methods for using the presence of such biomarkers to predict or diagnose organ or tissue rejection/injury or diabetes in a subject; and methods to select or modify a therapeutic regimen for a subject based on the use of such biomarkers.

公开(公告)号：US20240307325A1

公开(公告)日：2024-09-19

申请号：US18272486

申请日：2022-01-14

Applicant: Thomas Jefferson University

Inventor： Felix J. Kim

IPC: A61K31/155 ,  A61K31/7105 ,  A61K31/713 ,  A61P1/16 ,  A61P29/00 ,  C12N15/86 ,  G01N33/68

CPC classification number: A61K31/155 ,  A61K31/7105 ,  A61K31/713 ,  A61P1/16 ,  A61P29/00 ,  C12N15/86 ,  G01N33/6893 ,  C12N2740/15043 ,  G01N2333/705 ,  G01N2800/085 ,  G01N2800/50

Abstract: The present disclosure relates to the finding that certain compounds that modulate the activity(ies) of Sigma receptors can be used to treating or ameliorate nonalcoholic fatty liver disease and related diseases or disorders. In certain embodiments, the Sigma receptor is a Sigma-I receptor (also known as Sigma I).

公开(公告)号：US20240298956A1

公开(公告)日：2024-09-12

申请号：US18588150

申请日：2024-02-27

Applicant: Abbott Laboratories

Inventor： Beth McQuiston ,  Frederick Korley ,  Agim Beshiri ,  Jaime Marino ,  Saul Datwyler

IPC: A61B5/00 ,  C12Q1/6883 ,  G01N33/533 ,  G01N33/543 ,  G01N33/564 ,  G01N33/577 ,  G01N33/68

CPC classification number: A61B5/4064 ,  G01N33/54346 ,  G01N33/54366 ,  G01N33/577 ,  G01N33/6896 ,  C12Q1/6883 ,  G01N33/533 ,  G01N33/564 ,  G01N33/6893 ,  G01N2800/28 ,  G01N2800/52 ,  G01N2800/56 ,  G01N2800/60

Abstract: Disclosed herein are methods that aid in the diagnosis and evaluation of a human subject that has sustained or may have sustained an injury to the head, such as mild or a moderate, severe, or moderate to severe traumatic brain injury (TBI), by detecting levels of cardiac troponin I (cTnI) and one or more early biomarkers which are not cTnI, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof, in biological samples taken from a human subject at time points within about 24 hours of injury after the subject has sustained or may have sustained the injury to the head.

公开(公告)号：US20240295566A1

公开(公告)日：2024-09-05

申请号：US18169934

申请日：2023-02-16

Applicant: Centre for Chinese Herbal Medicine Drug Development Limited

Inventor： Zhaoxiang BIAN ,  Hoi Leong Xavier WONG ,  Lixiang ZHAI ,  Johnson Yiu-Nam LAU ,  Chengyuan LIN ,  Haitao XIAO

IPC: G01N33/68 ,  A61K31/40 ,  A61K31/44 ,  A61P3/00 ,  G01N33/569

CPC classification number: G01N33/6893 ,  A61K31/40 ,  A61K31/44 ,  A61P3/00 ,  G01N33/56911 ,  G01N2800/04

Abstract: Provided herein is a method of diagnosing a metabolic disorder in a subject involving determining the amount of at least one of Ruminococcus gnavus, phenethylamine, and tryptamine in a fecal sample obtained from the subject. Also provided is a method of treating a metabolic disorder in a subject in need thereof involving the administration of a therapeutically effective amount of a trace amine-associated receptor 1 inhibitor.